The Wine Debate: Cardiovascular Benefits Vs Cancer Risks - Frankly Speaking Ep 422

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-422

Overview: Conflicting data on alcohol’s health effects leave clinicians uncertain about patient guidance. In this episode, we review the PREDIMED trial’s findings on wine and cardiovascular outcomes, explore objective biomarkers for intake, and examine the National Academy of Sciences’ recent report to clarify the risks and benefits of moderate consumption, giving you confidence in counseling patients.

Episode resource links:

• Inés Domínguez-López, Rosa M Lamuela-Raventós, Cristina Razquin, et al. Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial, European Heart Journal, 2024;, ehae804, https://doi.org/10.1093/eurheartj/ehae804

   

   

• National Academies of Sciences, Engineering, and Medicine. 2025. Review of Evidence on Alcohol and Health. Washington, DC: The National Academies Press. https://doi.org/10.17226/28582

   

Guest: Robert A. Baldor MD, FAAFP

Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com